{"timeline":{"headline":"A Safety and Efficacy Study of BOTOXÂ® in Korean Adults With Chronic Migraine","type":"default","text":"History of NCT02147561","startDate":"2014,05,23","date": [{"startDate":"2014,05,23","headline":"View of NCT02147561 on 2014_05_23","text":"<table class=\"info\">\n<tr>\n<th nowrap=\"\">ClinicalTrials Identifier:</th><td>NCT02147561</td>\n</tr>\n<tr>\n<th>Updated:</th><td>2014_05_23</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Descriptive Information</h2>\n</th>\n</tr>\n<tr>\n<th>Brief title</th><td>\n<p>A Safety and Efficacy Study of BOTOX\u00ae in Korean Adults With Chronic Migraine</p>\n</td>\n</tr>\n<tr>\n<th>Official title</th><td>\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Brief summary</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>This study will evaluate the safety and efficacy of BOTOX\u00ae treatment in Korean adults with chronic migraine.</p>\n</td>\n</tr>\n<tr>\n<th>Detailed description</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p></p>\n</td>\n</tr>\n<tr>\n<th>Phase</th><td>Phase 4</td>\n</tr>\n<tr>\n<th>Study type</th><td>Interventional</td>\n</tr>\n<tr>\n<th>Study design</th><td>Treatment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Open Label</td>\n</tr>\n<tr>\n<th>Study design</th><td>Single Group Assignment</td>\n</tr>\n<tr>\n<th>Study design</th><td>Safety/Efficacy Study</td>\n</tr>\n<tr>\n<th>Primary outcome</th><td>Measure: Percentage of Patients with Adverse Events<br/>Time Frame: 28 Days<br/>Safety Issue? No</td>\n</tr>\n<tr>\n<th>Secondary outcome</th><td>Measure: Change from Baseline in Headache Impact Test-6 (HIT-6) Total Score<br/>Time Frame: Baseline, Day 28<br/>Safety Issue? No</td>\n</tr>\n<tr>\n<th>Secondary outcome</th><td>Measure: Physician Global Assessment of Outcome on a 3-Point Scale<br/>Time Frame: Day 28<br/>Safety Issue? No</td>\n</tr>\n<tr>\n<th>Condition</th><td>\n         Migraine Disorders\n      </td>\n</tr>\n<tr>\n<th>Arm/Group</th><td>\n<div>Arm Label: botulinum toxin Type A      \n            \u00a0 \u00a0 \u00a0 \u00a0\n        Experimental</div>\n<p>Botulinum toxin Type A injected across specific head and neck muscles on Day 0.</p>\n</td>\n</tr>\n<tr>\n<th>Intervention</th><td>\n<div>Biological/Vaccine: botulinum toxin Type A\n            \u00a0 \u00a0 \u00a0 \u00a0\n            Arm Label: botulinum toxin Type A</div>\n<p>Botulinum toxin Type A injected across specific head and neck muscles on Day 0.</p>\n</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Recruitment Information</h2>\n</th>\n</tr>\n<tr>\n<th>Status</th><td>Not yet recruiting</td>\n</tr>\n<tr>\n<th>Start date</th><td>\n         2014-06\n      </td>\n</tr>\n<tr>\n<th>Last follow-up date</th><td>\n         2015-01\n      \n      (Anticipated)\n  </td>\n</tr>\n<tr>\n<th>Primary completion date</th><td>\n         2015-01\n      \n      (Anticipated)\n  </td>\n</tr>\n<tr>\n<th>Criteria</th>\n</tr>\n<tr>\n<td class=\"bigdent\" colspan=\"2\">\n<p>Inclusion Criteria:<br/> \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0- Ethnically Korean with a diagnosis of chronic migraine<br/>\n<br/> \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Exclusion Criteria:<br/> \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0- Anticipated need for botulinum toxin treatment for any reason other than chronic migraine during the study<br/> \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0- Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis</p>\n</td>\n</tr>\n<tr>\n<th>Gender</th><td>\n            Both\n         </td>\n</tr>\n<tr>\n<th>Minimum age</th><td>18 Years</td>\n</tr>\n<tr>\n<th>Healthy volunteers</th><td>No</td>\n</tr>\n<tr>\n<th class=\"section\" colspan=\"2\">\n<h2>Administrative Data</h2>\n</th>\n</tr>\n<tr>\n<th>Organization name</th><td>Allergan</td>\n</tr>\n<tr>\n<th>Organization study ID</th><td>191622-148</td>\n</tr>\n<tr>\n<th>Sponsor</th><td>\n               Allergan\n            </td>\n</tr>\n<tr>\n<th>Health Authority</th><td>\n               South Korea: Korea Food and Drug Administration (KFDA)\n         </td>\n</tr>\n</table>","asset":{"media":"","credit":"clinicaltrials.gov","caption":""}}]}}